Search Results

SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of synthetic availability from SyntheticMR’s SyMRI NEURO software at its facilities.

SyntheticMR announced that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510 clearance for clinical use in the United States.

SyntheticMR announced that they have expanded their partnership with Philips to include SyMRI 3D.

Vitrolife AB has completed the acquisition of eFertility as previously communicated in the press release on 2 May 2024.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.

Vitrolife AB signed an agreement to acquire 100% of the shares in eFertility. This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.

AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP.

The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.